Filter posts

BIO Investor Forum Explores “Digiceuticals” as a New Class of FDA-Approved Therapeutics

Within the past year, the FDA has launched a provider pre-certification program as a pilot …

Four Questions for the Energy and Commerce Hearing on 340B

Later this morning, the House Energy and Commerce Committee will hold a hearing to examine …

FDA Protects Patients While Promoting Innovation

Today, 83 percent of children with cancer survive, compared to just 58 percent in the …

Next Generation Approaches to Battling Pain and Addiction

What are the new and emerging scientific insights and approaches that offer hope for non-addictive …

#BIOCEO18: Tackling the Opioid Crisis

Opioid addiction is plaguing communities across the country, leaving in its wake countless victims, devastated …

#BIOCEO18: Paradigm Shift Creating New Opportunities in China

The past few years have been a time of tremendous change in the world’s second …

ICYMI: WSJ Editors on “Biotech’s Breakthrough Year”

2017 was an amazing year for biomedical advances, with 46 novel drug approvals, a near …

New Report Shows Outsized Impact of Tech-Based Startups on U.S. Economic Growth

A newly released report from the Information Technology & Innovation Foundation (ITIF) demonstrates the outsized …

ICYMI: A Bipartisan Drug Cartel?

“As false as it is implausible.” That’s how a Wall Street Journal editorial describes a …

#BIF17: Looking Ahead to 2018 Policy Landscape

The past year has seen a number of important changes in the legislative and policy …